

CORPORATE PROFILE

Knight Therapeutics Inc. (TSX: GUD) is a pan-American (ex-USA) specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America with over 150 products and over 20 partners. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight is headquartered in Montreal, Quebec, Canada and has over 800 employees.

OUR FOOTPRINT



~\$414M in Revenue and Adjusted Revenue¹



11 Countries + distributors in Central America and Caribbean



+800 Employees



+150 Products
>25 Pipeline & early launch products



+20 Partners



2 Manufacturing Plants
1 R&D Center
1 Regional Distribution Center

MARKET FACTS

(As at October 30, 2025)
 Symbol: TSX: GUD
 Share Price: \$5.83
 Shares Outstanding: 99.3 M
 Market Capitalization: \$578.9 M

MANAGEMENT TEAM

Samira Sakhia
 President and CEO

Amal Khouri
 Chief Business Officer

Arvind Utchanah
 Chief Financial Officer

Susan Emblem
 Global VP Human Resources

Monica Percario
 Global VP Regulatory and Quality

Leopoldo Bosano
 VP Manufacturing and Operations

Henrique Dias
 Global VP Marketing

Melanie Groleau
 Global VP Medical and Clinical

BOARD OF DIRECTORS

Jonathan Ross Goodman
 (Executive Chairman)

James Gale (Lead Director)

Samira Sakhia

Robert Lande

Janice Murray

Michael Tremblay

Nicolás Sujoy

INVESTOR CONTACT

Samira Sakhia
 Tel: 514.484.4483

Arvind Utchanah
 Tel: 598.2626.2344

E-mail: IR@knighttx.com
 Website: www.knighttx.com

FINANCIAL RESULTS

In '000s of CAD except per share amounts

	Q3 2025	Q3 2024	TTM Q3-25	TTM Q3-24
Revenues	121,548	92,263	413,846	348,637
Cash inflow from operations	10,163	5,016	35,554	52,754
<i>Non-GAAP measures:</i>				
Adjusted Revenue ^{1,2}	122,628	91,430	413,214	359,748
Adjusted EBITDA ^{1,3}	20,987	13,454	63,603	54,844
Per share ^{1,3}	0.21	0.13	0.64	0.54
	09-30-2025	12-31-2024		
Net cash ⁴ , marketable securities and financial assets	93,505	232,878		
Per share	0.94	2.30		
Net asset value	766,792	795,105		
Per share	7.69	7.85		


¹ Adjusted Revenue, Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies.

² Adjusted Revenue exclude impact of hyperinflation/ IAS29.


³ Adjusted EBITDA is operating income (loss) adjusted to exclude amortization and impairment of non-current assets, depreciation, impact of IAS 29 (accounting under hyperinflation), acquisition cost and non-recurring expenses but to include costs related to leases. Adjusted EBITDA per share is a non-GAAP ratio and calculated as adjusted EBITDA over number of common shares outstanding at the end of the respective period.

⁴ Net of bank loans


ADJUSTED REVENUE¹ BY PRODUCT PORTFOLIO²



ADJUSTED REVENUE¹ BY GEOGRAPHY²



HEADCOUNT BY GEOGRAPHY³




² TTM Q3 2025


³ As at October 15, 2025

FINANCIAL HIGHLIGHTS

Adjusted Revenue¹ by Therapeutic Area



Adjusted EBITDA¹ and Cash Flow from Operations



¹ Adjusted Revenues is a non-GAAP measure and exclude impact of hyperinflation/ IAS29. Adjusted EBITDA is a non-GAAP measure and defined as operating income or loss adjusted to exclude amortization and impairment of non-current assets, depreciation, impact of IAS 29 (accounting under hyperinflation), acquisition cost and non-recurring expenses but to include costs related to leases. Adjusted EBITDA per share is a non-GAAP ratio and calculated as adjusted EBITDA over number of common shares outstanding at the end of the respective period.

² CAGR represents the compound annual growth rate which is calculated as (Adjusted Revenue for TTM Q3 2025 divided by the Adjusted Revenue for TTM Q3 2020)^(1 divided by number of years).

CORPORATE RESPONSIBILITY

Knight focuses on acquiring, in-licensing and commercializing innovative products, as well as developing, manufacturing and marketing specialty pharmaceutical products in Latin America, Canada and select international markets.

Knight continues to work diligently to ensure patients have access to Knight's medications in its markets, as well as develop branded generic products for Latin America to ensure that Knight provides cost effective treatments.

INVESTMENT HIGHLIGHTS

- Strong regional infrastructure with a unique footprint in Canada and across 10 countries in Latin America
- Experienced and dynamic management team
- Proven ability to develop a rich pipeline of new products and to secure mutually beneficial transactions
- Proven track record of profitable growth
- Financial strength to execute our strategy

ANALYST COVERAGE

Bloom Burton & Co.
David Martin
dmartin@bloomburton.com

Canaccord Genuity
Tania Armstrong-Whitworth
tarmstrongwhitworth@cgf.com

Raymond James
Michael Freeman
michael.freeman@raymondjames.ca

Stifel GMP
Justin Keywood
jkeywood@stifel.com

Research Capital
Andre Uddin
auddin@researchcapital.com

Paradigm Capital Inc
Scott McAuley
smcauley@paradigmcap.com

RBC Capital Markets
Douglas Miehm
douglas.miehm@research.rbccm.com

¹Adjusted Revenue and Adjusted EBITDA are non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies.